Intraoperative Radiotherapy Specialist

Dennis R. Holmes, M.D., F.A.C.S. -  - Breast Cancer Surgeon

Dennis R. Holmes, M.D., F.A.C.S.

Breast Cancer Surgeon located in Santa Monica, CA, Los Angeles, CA and Glendale, CA

As National Co-Chair of the TARGIT U.S. Registry clinical trial and President of the TARGIT Collaborative Group, breast surgeon Dennis R. Holmes, M.D., F.A.C.S., is a world-recognized expert in targeted intraoperative radiotherapy (TARGIT) with offices in Santa Monica, Glendale, and Los Angeles, California.

Intraoperative Radiotherapy Q & A

What is targeted intraoperative radiotherapy?

TARGeted Intraoperative radioTherapy (TARGIT) is a form of breast radiation that is administered as a single treatment at the time of lumpectomy to reduce the risk of cancer recurrence.  TARGIT is a type of partial breast irradiation which targets radiation to the tumor site but spares the rest of the breast and surrounding tissues the effects of radiation.   TARGIT takes only 30 minutes to deliver.  By comparison, traditional whole breast radiotherapy administers radiation to the whole breast, chest wall, and nearby organs, and takes 3-6 weeks to complete.




What are the advantages of TARGIT versus traditional radiotherapy?

TARGIT is very convenient compared to traditional radiotherapy.  TARGIT requires only a 30-minute treatment which is entirely given while the patient is asleep during lumpectomy surgery.  For most patients, TARGIT completely eliminates the needs for the 3-6 week course of traditional whole breast radiation normally required after lumpectomy surgery.

Also, TARGIT reduces the overall side effects of radiation by targeting and confining the radiation dose to the part of the breast from which the cancer was removed.  

Most importantly, a large international study called the TARGIT-A Trial showed TARGIT to be equally effective as traditional whole breast radiotherapy at reducing the risk of cancer recurrence after lumpectomy.

Why should I choose Dr. Holmes for TARGIT?

Dr. Holmes is one of the world’s leading authorities in the field, with more than a decade of experience in using this procedure. He lectures internationally on TARGIT and conducts groundbreaking research on its effects as co-chair of the United States Targeted Intraoperative Radiotherapy Steering Committee. Dr. Holmes also serves as President and Chair of the TARGIT Collaborative Group, a national organization that educates physicians and patients about breast cancer treatment advancements that reduce the burden and side effects of breast cancer surgery and radiotherapy.

Am I a candidate for TARGIT?

If you’ve been diagnosed with breast cancer and are considering a lumpectomy, you may be eligible for TARGIT if you meet the following criteria:

  • Age 40 or older have breast cancer in only one part of the breast
  • Have breast cancer treatable with lumpectomy
  • Have a tumor that is 3cm (1.5 inches) or smaller
  • Don’t have any signs of cancer in the lymph nodes

Is TARGIT safe and effective?

TARGIT was shown to be as safe as traditional whole breast radiotherapy in a large, international study called the TARGIT-A Trial. The study showed that TARGIT administered at the time of cancer removal was equally effective as traditional whole breast radiotherapy at preventing breast cancer recurrence in women with early-stage breast cancer.

For more information about intraoperative radiotherapy, visit Dr. Holmes’s YouTube Channel here

Our Locations

Choose your preferred location